Fragment Covalent Bond Formation at SOS1 Tyr-884 Inhibits KRAS Nucleotide Exchange
Preprint
Abstract
The activation of the KRAS oncogene from its inactive GDP-bound state to its active GTP-bound state is mediated by Son of Sevenless (SOS) exchange factors. Small-molecule inhibition of SOS1 has been achieved, with three compounds currently in clinical trials. These compounds bind to SOS1 and disrupt a crucial interaction between SOS1 Tyr-884 and KRAS Arg-73. Here, we screen libraries of aryl sulfonyl fluorides to explore covalent bond formation at Tyr-884 as a strategy for covalent inhibition of SOS1•KRAS binding. Initially, ten fragments were tested and several inhibited KRAS nucleotide exchange by SOS1. X-ray crystal structures revealed that one reaction site for the fragments was Tyr-884, but mass spectrometry and nucleotide exchange assays with wild-type and mutant SOS1 indicated additional reaction sites. To identify candidates specific to Tyr-884, we conducted a larger screen and identified fragment 11 (SOF-599). The fragment formed an adduct predominantly at Tyr-884 and inhibited KRAS nucleotide exchange by SOS1 in a time- and concentration-dependent manner. Fragment 11 (SOF-599) exhibited a half-maximal inactivation concentration ( K I ) of 12 µM and a reaction half-life of 6 h. These findings establish 11 (SOF-599) as a promising starting point for the development of covalent SOS1 inhibitors as an alternative strategy to existing non-covalent antagonists.Keywords
This publication has 22 references indexed in Scilit:
- Accelerating SuFEx Reactions via Aryl Fluorosulfate Structural Engineering for Enhanced Covalent Targeted Cancer TherapyAngewandte Chemie International Edition, 2026
- An Investigation into the In Vitro Metabolic Stability of Aryl Sulfonyl Fluorides for their Application in Medicinal Chemistry and RadiochemistryMolecular Pharmaceutics, 2023
- Chemical and biology of sulfur fluoride exchange (SuFEx) click chemistry for drug discoveryBioorganic Chemistry, 2022
- Covalent Fragment Screening Identifies Rgl2 RalGEF Cysteine for Targeted Covalent Inhibition of Ral GTPase ActivationChemMedChem, 2022
- Sotorasib for Lung Cancers with KRAS p.G12C MutationNew England Journal of Medicine, 2021
- One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRASJournal of Medicinal Chemistry, 2021
- KRAS G12C Inhibition with Sotorasib in Advanced Solid TumorsNew England Journal of Medicine, 2020
- Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RASACS Medicinal Chemistry Letters, 2018
- Sulfonyl fluorides as privileged warheads in chemical biologyChemical Science, 2015
- Chronicles of the GTPase switchNature Chemical Biology, 2011